Overactive bladder – 18 years – Part II

ABSTRACT Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder.

Guardado en:
Detalles Bibliográficos
Autores principales: Truzzi,Jose Carlos, Gomes,Cristiano Mendes, Bezerra,Carlos A., Plata,Ivan Mauricio, Campos,Jose, Garrido,Gustavo Luis, Almeida,Fernando G., Averbeck,Marcio Augusto, Fornari,Alexandre, Salazar,Anibal, Dell’Oro,Arturo, Cintra,Caio, Sacomani,Carlos Alberto Ricetto, Tapia,Juan Pablo, Brambila,Eduardo, Longo,Emilio Miguel, Rocha,Flavio Trigo, Coutinho,Francisco, Favre,Gabriel, Garcia,José Antonio, Castaño,Juan, Reyes,Miguel, Leyton,Rodrigo Eugenio, Ferreira,Ruiter Silva, Duran,Sergio, López,Vanda, Reges,Ricardo
Formato: Digital revista
Idioma:English
Publicado: Sociedade Brasileira de Urologia 2016
Acceso en línea:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S1677-55382016000200199
record_format ojs
spelling oai:scielo:S1677-553820160002001992016-05-19Overactive bladder – 18 years – Part IITruzzi,Jose CarlosGomes,Cristiano MendesBezerra,Carlos A.Plata,Ivan MauricioCampos,JoseGarrido,Gustavo LuisAlmeida,Fernando G.Averbeck,Marcio AugustoFornari,AlexandreSalazar,AnibalDell’Oro,ArturoCintra,CaioSacomani,Carlos Alberto RicettoTapia,Juan PabloBrambila,EduardoLongo,Emilio MiguelRocha,Flavio TrigoCoutinho,FranciscoFavre,GabrielGarcia,José AntonioCastaño,JuanReyes,MiguelLeyton,Rodrigo EugenioFerreira,Ruiter SilvaDuran,SergioLópez,VandaReges,Ricardo Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics ABSTRACT Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.42 n.2 20162016-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199en10.1590/S1677-5538.IBJU.2015.0367
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Truzzi,Jose Carlos
Gomes,Cristiano Mendes
Bezerra,Carlos A.
Plata,Ivan Mauricio
Campos,Jose
Garrido,Gustavo Luis
Almeida,Fernando G.
Averbeck,Marcio Augusto
Fornari,Alexandre
Salazar,Anibal
Dell’Oro,Arturo
Cintra,Caio
Sacomani,Carlos Alberto Ricetto
Tapia,Juan Pablo
Brambila,Eduardo
Longo,Emilio Miguel
Rocha,Flavio Trigo
Coutinho,Francisco
Favre,Gabriel
Garcia,José Antonio
Castaño,Juan
Reyes,Miguel
Leyton,Rodrigo Eugenio
Ferreira,Ruiter Silva
Duran,Sergio
López,Vanda
Reges,Ricardo
spellingShingle Truzzi,Jose Carlos
Gomes,Cristiano Mendes
Bezerra,Carlos A.
Plata,Ivan Mauricio
Campos,Jose
Garrido,Gustavo Luis
Almeida,Fernando G.
Averbeck,Marcio Augusto
Fornari,Alexandre
Salazar,Anibal
Dell’Oro,Arturo
Cintra,Caio
Sacomani,Carlos Alberto Ricetto
Tapia,Juan Pablo
Brambila,Eduardo
Longo,Emilio Miguel
Rocha,Flavio Trigo
Coutinho,Francisco
Favre,Gabriel
Garcia,José Antonio
Castaño,Juan
Reyes,Miguel
Leyton,Rodrigo Eugenio
Ferreira,Ruiter Silva
Duran,Sergio
López,Vanda
Reges,Ricardo
Overactive bladder – 18 years – Part II
author_facet Truzzi,Jose Carlos
Gomes,Cristiano Mendes
Bezerra,Carlos A.
Plata,Ivan Mauricio
Campos,Jose
Garrido,Gustavo Luis
Almeida,Fernando G.
Averbeck,Marcio Augusto
Fornari,Alexandre
Salazar,Anibal
Dell’Oro,Arturo
Cintra,Caio
Sacomani,Carlos Alberto Ricetto
Tapia,Juan Pablo
Brambila,Eduardo
Longo,Emilio Miguel
Rocha,Flavio Trigo
Coutinho,Francisco
Favre,Gabriel
Garcia,José Antonio
Castaño,Juan
Reyes,Miguel
Leyton,Rodrigo Eugenio
Ferreira,Ruiter Silva
Duran,Sergio
López,Vanda
Reges,Ricardo
author_sort Truzzi,Jose Carlos
title Overactive bladder – 18 years – Part II
title_short Overactive bladder – 18 years – Part II
title_full Overactive bladder – 18 years – Part II
title_fullStr Overactive bladder – 18 years – Part II
title_full_unstemmed Overactive bladder – 18 years – Part II
title_sort overactive bladder – 18 years – part ii
description ABSTRACT Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder.
publisher Sociedade Brasileira de Urologia
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199
work_keys_str_mv AT truzzijosecarlos overactivebladder18yearspartii
AT gomescristianomendes overactivebladder18yearspartii
AT bezerracarlosa overactivebladder18yearspartii
AT plataivanmauricio overactivebladder18yearspartii
AT camposjose overactivebladder18yearspartii
AT garridogustavoluis overactivebladder18yearspartii
AT almeidafernandog overactivebladder18yearspartii
AT averbeckmarcioaugusto overactivebladder18yearspartii
AT fornarialexandre overactivebladder18yearspartii
AT salazaranibal overactivebladder18yearspartii
AT delloroarturo overactivebladder18yearspartii
AT cintracaio overactivebladder18yearspartii
AT sacomanicarlosalbertoricetto overactivebladder18yearspartii
AT tapiajuanpablo overactivebladder18yearspartii
AT brambilaeduardo overactivebladder18yearspartii
AT longoemiliomiguel overactivebladder18yearspartii
AT rochaflaviotrigo overactivebladder18yearspartii
AT coutinhofrancisco overactivebladder18yearspartii
AT favregabriel overactivebladder18yearspartii
AT garciajoseantonio overactivebladder18yearspartii
AT castanojuan overactivebladder18yearspartii
AT reyesmiguel overactivebladder18yearspartii
AT leytonrodrigoeugenio overactivebladder18yearspartii
AT ferreiraruitersilva overactivebladder18yearspartii
AT duransergio overactivebladder18yearspartii
AT lopezvanda overactivebladder18yearspartii
AT regesricardo overactivebladder18yearspartii
_version_ 1756428193988870144